- In a recent Nature article, MSKCC researchers in collaboration with researchers from several other institutions offered a genetic explanation for why people with lung cancer respond differently to erlotinib.
- James P. Allison, head of the immunology program at MSKCC, was quoted in a New York Times article about the recent FDA approved drug Yervoy, the first drug shown to prolong the lives of people with the skin cancer melanoma.